Abstract
Two doses of the BNT162b2 mRNA vaccine are highly effective against SARS-CoV-2. Here, we tested the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2. Serum from vaccinated individuals was serially tested for its ability to neutralize wild-type SARS-CoV-2 (USA-WA1/2020) and an engineered USA-WA1/2020 bearing the Omicron spike glycoprotein. At 2 or 4 weeks post dose 2, the neutralization geometric mean titers (GMTs) against the wild-type and Omicron-spike viruses were 511 and 20, respectively; at 1 month post dose 3, the neutralization GMTs increased to 1,342 and 336; and at 4 months post dose 3, the neutralization GMTs decreased to 820 and 171. The data support a 3-dose vaccination strategy and provide a glimpse into the durability of the neutralization response against Omicron.
Keywords: BNT162b2 vaccine; Pfizer vacine; SARS-CoV-2; neutralization; neutralization durability; variants.
【저자키워드】 SARS-CoV-2, BNT162b2 vaccine, neutralization, variants., Pfizer vacine, neutralization durability, 【초록키워드】 viruses, neutralization, spike glycoprotein, omicron, variants, BNT162b2, Pfizer, serum, Antibody neutralization, BNT162b2 mRNA vaccine, dose, Vaccination strategy, geometric mean, Support, GMTs, wild-type SARS-CoV-2, wild-type, vaccinated individuals, USA-WA1/2020, geometric mean titer, vaccinated individual, effective, neutralize, tested, virus, GMT, of BNT162b2, 【제목키워드】 dose,